Ticker Details
Halozyme Therapeutics, Inc. Halozyme Therapeutics Inc is a biotechnology company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.
IPO Date:	March 16, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$9.33B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.48 | 2.39%
Avg Daily Range (30 D):	$1.29 | 1.80%
Avg Daily Range (90 D):	$1.17 | 1.73%

Institutional Daily Volume
Avg Daily Volume:	.84M
Avg Daily Volume (30 D):	1.47M
Avg Daily Volume (90 D):	1.31M

Trade Size
Avg Trade Size (Sh.):	101
Avg Trade Size (Sh.) (30 D):	55
Avg Trade Size (Sh.) (90 D):	53

Institutional Trades
Total Institutional Trades:	11,061
Avg Institutional Trade:	$3.23M
Avg Institutional Trade (30 D):	$6.53M
Avg Institutional Trade (90 D):	$5.53M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$6.63M
Avg Closing Trade (30 D):	$24.84M
Avg Closing Trade (90 D):	$20.56M
Avg Closing Volume:	168.77K

News

Jun 22, 2026 @ 12:00 PM LifeMD Announces Exclusive Collaboration to Launch... Source: Lifemd, Inc.

May 5, 2026 @ 8:00 PM Acumen Pharmaceuticals to Report First Quarter Fin... Source: Na

Mar 19, 2026 @ 8:00 PM Acumen Pharmaceuticals to Report Fourth Quarter an... Source: Na

Mar 10, 2026 @ 8:00 PM Acumen Pharmaceuticals to Participate in the Stife... Source: Na

Jan 28, 2026 @ 6:58 PM Halozyme Therapeutics Projects Sustained Growth We... Source: Vandana Singh

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$2.96	$1.27	$-1.16
Diluted EPS	$2.86	$1.22	$-1.12
Revenue	$1.51B	$376.71M	$451.77M
Gross Profit	$1.25B	$297.47M	$373M
Net Income / Loss	$348.84M	$150.05M	$-141.59M
Operating Income / Loss	$511.99M	$184.52M	$-92.89M
Cost of Revenue	$259.61M	$79.24M	$78.77M
Net Cash Flow	$135.68M	$175.59M	$-283.24M
PE Ratio